MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Abeona Therapeutics Company Profile (NASDAQ:ABEO)

Consensus Ratings for Abeona Therapeutics (NASDAQ:ABEO) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.25 (417.58% upside)

Analysts' Ratings History for Abeona Therapeutics (NASDAQ:ABEO)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/24/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016Rodman & RenshawReiterated RatingBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015MLV & Co.Initiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/11/2015Roth CapitalInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2015HC WainwrightInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Abeona Therapeutics (NASDAQ:ABEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/16/2016        
5/16/2016Q1($0.13)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2016Q415($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/20/2015Q215($0.10)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Abeona Therapeutics (NASDAQ:ABEO)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Abeona Therapeutics (NASDAQ:ABEO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Abeona Therapeutics (NASDAQ:ABEO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/31/2015Mark J AhnDirectorBuy18,182$5.50$100,001.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Mark J AhnDirectorBuy25,000$4.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2014Steven H RouhandehDirectorBuy250,000$4.00$1,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Abeona Therapeutics (NASDAQ:ABEO)
DateHeadline
06/24/16 02:16 PMNew Broker Ratings For Abeona Therapeutics Inc. (ABEO) - FTSE News
06/24/16 02:16 PMShare Volatility Check for: Abeona Therapeutics Inc. (NASDAQ:ABEO) - Press Telegraph
06/22/16 02:16 PMAbeona Therapeutics Inc. (NasdaqCM:ABEO) Stock Momentum Hits Weakness - CML News
06/21/16 11:45 AMETF’s with exposure to Abeona Therapeutics, Inc. : June 21, 2016 -
06/20/16 08:48 AMThis Weeks Broker Views For Abeona Therapeutics Inc. (ABEO) - Fiscal Standard
06/07/16 04:26 PMETF’s with exposure to Abeona Therapeutics, Inc. : June 7, 2016 -
06/07/16 10:40 AMAbeona Therapeutics to Present at Jefferies 2016 Global Healthcare Conference - Marketwired (press release)
06/06/16 11:14 AMAbeona Therapeutics, Inc. :ABEO-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/04/16 10:43 AMAbeona Therapeutics to Present at 2016 BIO International Convention - Yahoo Finance UK
06/03/16 08:17 PMInvestigation for Investors in Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Announced
06/02/16 08:12 PMInvestigation for Investors in Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Announced - Digital Journal - Investigation for Investors in Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) AnnouncedDigital JournalDallas, TX based Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for rare disease. Abeona Therapeutics Inc reported that its annual Total Revenue rose from $.93 million in 2014 to $1.04 million in 2015 and that ...
06/02/16 10:53 AMAbeona Therapeutics to Present at 2016 BIO International Convention - Marketwired (press release) - Abeona Therapeutics to Present at 2016 BIO International ConventionMarketwired (press release)NEW YORK, NY AND CLEVELAND, OH--(Marketwired - June 02, 2016) - Abeona Therapeutics Inc. ( NASDAQ : ABEO) a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based products for severe and ...Analyst Review: Abeona Therapeutics Inc. (ABEO)Risers & Fallersall 2 news articles »
06/02/16 06:15 AMAbeona Therapeutics to Present at 2016 BIO International Convention - [at noodls] - NEW YORK, NY AND CLEVELAND, OH -- (Marketwired) -- 06/02/16 -- Abeona Therapeutics Inc.(NASDAQ: ABEO)a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based products ...
05/31/16 07:55 AMAbeona Therapeutics (ABEO) – Analysts' Weekly Ratings Changes - Let Me Know About This - Abeona Therapeutics (ABEO) – Analysts' Weekly Ratings ChangesLet Me Know About ThisShares of Abeona Therapeutics Inc (NASDAQ:ABEO) traded up 1.24% during trading on Monday, hitting $3.26. The company had a trading volume of 141,167 shares. Abeona Therapeutics Inc has a 52-week low of $2.05 and a 52-week high of $8.66.
05/26/16 01:50 PMAbeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Phase 1/2 Clinical Study With ... - Marketwired (press release) - Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Phase 1/2 Clinical Study With ...Marketwired (press release)Abeona Therapeutics Inc. ( NASDAQ : ABEO), a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced the FDA has allowed an ...Abeona Therapeutics Receives FDA Approval for Study of ABO-101 to Treat Sanfilippo Syndrome; Shares Flat Early ...Sonoran Weekly Reviewall 2 news articles »
05/24/16 01:55 PMRevenue Update on Abeona Therapeutics Inc(NASDAQ:ABEO) - Trade Calls - Revenue Update on Abeona Therapeutics Inc(NASDAQ:ABEO)Trade CallsAbeona Therapeutics Inc(NASDAQ:ABEO) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 17, 2016. Company reported revenue of $235.00K. Analysts estimated a revenue of $360.00K. Earnings ...Abeona Therapeutics to Present at UBS 2016 Global Healthcare ConferenceMarketwired (press release)Analyst Review: Abeona Therapeutics Inc. (ABEO)Risers & FallersAbeona Therapeutics Incorporated (NASDAQ:ABEO) Shorted Shares Increased By 0.83%Franklin IndependentThe Postall 5 news articles »
05/24/16 01:55 PMAbeona Therapeutics (ABEO) IND App for ABO-101 Phase 1/2 Allowed by U.S. FDA - StreetInsider.com - Abeona Therapeutics (ABEO) IND App for ABO-101 Phase 1/2 Allowed by U.S. FDAStreetInsider.comAbeona Therapeutics Inc. announced the FDA has allowed an Investigational New Drug (IND) Application for its Phase 1/2 Clinical Study with gene therapy candidate ABO-101 (AAV-NAGLU) for patients with Sanfilippo syndrome type B (MPS IIIB) to be ...and more »
05/24/16 06:16 AMAbeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Phase 1/2 Clinical Study With ABO-101 Gene Therapy for Patients With Sanfilippo Syndrome Type B (MPS IIIB) - [at noodls] - NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 05/24/16 -- Abeona Therapeutics Inc. (NASDAQ: ABEO) ABO-101 is Abeona's second AAV gene therapy to commence clinical trials in a rare CNS disease The ...
05/24/16 06:05 AM7:05 am Abeona Therapeutics announces FDA has allowed IND application for phase 1/2 clinical study with gene therapy candidate ABO-101 for patients with Sanfilippo syndrome type B to be conducted at Nationwide Children's Hospital -
05/23/16 01:16 PMAbeona Therapeutics to Present at UBS 2016 Global Healthcare Conference - [at noodls] - NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 05/23/16 -- Abeona Therapeutics Inc.(NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing and delivering gene therapy and plasma-based ...
05/20/16 01:18 PMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Violations of Delaware Law by Certain Officers and Directors of Abeona Therapeutics Inc. - [Business Wire] - Levi & Korsinsky announces it has commenced an investigation of Abeona Therapeutics Inc. concerning possible violations of Delaware law. To obtain additional inf
05/17/16 03:40 PMABEONA THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/17/16 07:42 AMAbeona Therapeutics Doses First Patient in Phase 1/2 Trial With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA) - [at noodls] - NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 05/17/16 -- Abeona Therapeutics Inc.(NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing products for severe and life-threatening ...
05/16/16 05:30 PMAbeona Therapeutics reports 1Q loss -
05/16/16 04:18 PMABEONA THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report -
05/16/16 04:12 PMAbeona Therapeutics Announces First Quarter 2016 Summary Financial Results and Recent Operational Highlights - [at noodls] - NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 05/16/16 -- Abeona Therapeutics Inc.(NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing and delivering gene therapy and plasma-based ...
05/15/16 01:43 PMAre Analysts Bullish Abeona Therapeutics Inc (NASDAQ:ABEO) After Last Week? - Wall Street Hints and News - Are Analysts Bullish Abeona Therapeutics Inc (NASDAQ:ABEO) After Last Week?Wall Street Hints and NewsAbeona Therapeutics has been the topic of 2 analyst reports since December 16, 2015 according to StockzIntelligence Inc. Rodman & Renshaw reinitiated the stock on April 20 with “Buy” rating. Below is a list of Abeona Therapeutics Inc (NASDAQ:ABEO) ...
05/12/16 01:40 PMBroker Outlook For Abeona Therapeutics Inc. (ABEO) - Share Trading News - Broker Outlook For Abeona Therapeutics Inc. (ABEO)Share Trading NewsAbeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for rare diseases. The Company's programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for ...
05/04/16 01:15 PMLatest Analyst Ratings For Abeona Therapeutics Inc. (ABEO) - Share Trading News - Latest Analyst Ratings For Abeona Therapeutics Inc. (ABEO)Share Trading News04/20/2016 – Abeona Therapeutics Inc. had its “buy” rating reiterated by analysts at Rodman & Renshaw. They now have a USD 17 price target on the stock. 12/15/2015 – Maxim Group began new coverage on Abeona Therapeutics Inc. giving the company a ...Abeona Therapeutics (ABEO) Sees Hammer Chart Pattern: Time to Buy?Zacks.comAbeona Therapeutics Incorporated (NASDAQ:ABEO) Sellers Covered 4.01% of Their ShortsB.O.D.Y Confidentialall 4 news articles »
05/04/16 07:48 AMAbeona Therapeutics (ABEO) Sees Hammer Chart Pattern: Time to Buy? -
05/03/16 01:30 PMAbeona Therapeutics Appoints Christine Silverstein as Vice President of Investor Relations - Marketwired (press release) - Abeona Therapeutics Appoints Christine Silverstein as Vice President of Investor RelationsMarketwired (press release)NEW YORK, NY, and CLEVELAND, OH--(Marketwired - May 03, 2016) - Abeona Therapeutics Inc ( NASDAQ : ABEO), a biopharmaceutical company focused on developing and delivering products for severe and life-threatening rare diseases, announced ...
05/03/16 01:30 PMBRIEF-Abeona Therapeutics appoints Christine Silverstein - Reuters - BRIEF-Abeona Therapeutics appoints Christine SilversteinReutersBRIEF-Abeona Therapeutics appoints Christine Silverstein. May 3 Abeona Therapeutics Inc. * Abeona therapeutics appoints christine silverstein as vice president of investor relations Source text for Eikon: Further company coverage: (Bengaluru Newsroom: ...
05/03/16 07:30 AMAbeona Therapeutics Appoints Christine Silverstein as Vice President of Investor Relations - [at noodls] - NEW YORK, NY, and CLEVELAND, OH -- (Marketwired) -- 05/03/16 -- Abeona Therapeutics Inc(NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering products for severe and life-threatening ...
04/28/16 01:29 PMBroker Outlook For The Week Ahead Abeona Therapeutics Inc. (ABEO) - Share Trading News - Broker Outlook For The Week Ahead Abeona Therapeutics Inc. (ABEO)Share Trading NewsAbeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for rare diseases. The Company's programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for ...
04/28/16 01:29 PMAbeona Therapeutics Inc. (ABEO) Updated Broker Price Targets - Share Trading News - Abeona Therapeutics Inc. (ABEO) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Abeona Therapeutics Inc. (ABEO). The latest reports which are currently in issue on Thursday 28th of April state 0 analysts have a rating of “strong buy”, 0 analysts ...Abeona Therapeutics Inc (ABEO) Upgraded at Zacks Investment ResearchWeb Breaking Newsall 2 news articles »
04/20/16 01:41 PMRodman & Renshaw Reiterates a Buy Rating on Abeona Therapeutics - Markets.co - Rodman & Renshaw Reiterates a Buy Rating on Abeona TherapeuticsMarkets.coAccording to The Fly, in a report released today, Ram Selvaraju from Rodman & Renshaw reiterated a Buy rating on Abeona Therapeutics (NASDAQ: ABEO), with a price target of $17. The company's shares opened today at $2.86, close to its 52-week low of ...
04/19/16 10:36 AMETF’s with exposure to Abeona Therapeutics, Inc. : April 19, 2016 -
04/18/16 01:51 PMKite Pharma Inc (NASDAQ:KITE) & Abeona Therapeutics (NASDAQ:ABEO) Stock's Buzzers - Wall Street 24 - Wall Street 24Kite Pharma Inc (NASDAQ:KITE) & Abeona Therapeutics (NASDAQ:ABEO) Stock's BuzzersWall Street 24Joseph Stanley is an asset manager at Hebba Alternative Investments with a focus on real assets. In his articles he likes to focus on events that affect the macro environment for assets (especially gold and silver), and introduce readers to different ...and more »
04/16/16 01:07 PMAbeona Therapeutics to Present at Gene, Cell and Molecular Therapies for Inherited Metabolic Diseases Meeting - Marketwired (press release) - Abeona Therapeutics to Present at Gene, Cell and Molecular Therapies for Inherited Metabolic Diseases MeetingMarketwired (press release)NEW YORK, NY, and CLEVELAND, OH--(Marketwired - April 15, 2016) - Abeona Therapeutics, Inc. ( NASDAQ : ABEO), a clinical stage biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe ...What Next for Abeona Therapeutics Inc Stock After Today's Huge Increase?RiversideGazette.comAbeona Therapeutics CEO to Present at Gene, Cell & Molecular Therapies for Inherited Metabolic Diseases Conf ...Sonoran Weekly ReviewZacks: Analysts Set $12.00 Target Price for Abeona Therapeutics Inc (NASDAQ:ABEO)Mas Market NewsFranklin Independentall 6 news articles »
04/15/16 07:19 AMAbeona Therapeutics to Present at Gene, Cell and Molecular Therapies for Inherited Metabolic Diseases Meeting - [at noodls] - NEW YORK, NY, and CLEVELAND, OH -- (Marketwired) -- 04/15/16 -- Abeona Therapeutics, Inc. (NASDAQ: ABEO), a clinical stage biopharmaceutical company focused on developing and delivering gene therapy and ...
04/12/16 01:32 PMNew Analyst Ratings On Abeona Therapeutics Inc. (ABEO) - Risers & Fallers - New Analyst Ratings On Abeona Therapeutics Inc. (ABEO)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Abeona Therapeutics Inc. (ABEO). The latest broker reports which are currently outstanding on Tuesday 12th of April state 1 analyst has a rating of “strong buy”, 3 ...
04/11/16 01:50 PMAbeona Therapeutics Incorporated (NASDAQ:ABEO) Sellers Increased By 1.18% Their Shorts - RiversideGazette.com - Abeona Therapeutics Incorporated (NASDAQ:ABEO) Sellers Increased By 1.18% Their ShortsRiversideGazette.comThe short interest to Abeona Therapeutics Incorporated's float is 9.47%. The stock decreased 4.00% or $0.11 on April 8, hitting $2.64. Abeona Therapeutics Inc (NASDAQ:ABEO) has declined 45.23% since September 2, 2015 and is downtrending.
04/10/16 01:47 PMIs Abeona Therapeutics Inc a Sell? The Stock Declines Again - RiversideGazette.com - Is Abeona Therapeutics Inc a Sell? The Stock Declines AgainRiversideGazette.comThe stock of Abeona Therapeutics Inc (NASDAQ:ABEO) is a huge mover today! The stock decreased 4.00% or $0.11 on April 8, hitting $2.64. About 60,039 shares traded hands. Abeona Therapeutics Inc (NASDAQ:ABEO) has declined 45.23% since ...
04/08/16 01:37 PMAbeona Therapeutics Inc. (ABEO) Latest Broker Coverage - Risers & Fallers - Abeona Therapeutics Inc. (ABEO) Latest Broker CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Abeona Therapeutics Inc. (ABEO). According to the latest broker reports outstanding on Friday 8th of April, 1 analyst has a rating of “strong buy”, 3 analysts “buy ...
04/06/16 03:57 PMETF’s with exposure to Abeona Therapeutics, Inc. : April 6, 2016 -
03/10/16 08:03 AMAbeona Therapeutics to Present at the 28th Annual ROTH Conference - [Marketwired] - Abeona Therapeutics, Inc. , a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that President ...
03/08/16 08:23 AMAbeona Therapeutics Announces Fourth Quarter and Full Year 2015 Summary Financial Results and Recent Operational Highlights - [Marketwired] - Abeona Therapeutics, Inc. , a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced summary ...
03/02/16 07:19 AMAbeona Therapeutics Highlights New Preclinical Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) Data at WORLDSymposium(TM) 2016 - [Marketwired] - AB0-201 demonstrates promising in vivo efficacy in preclinical models IND enabling toxicology to commence in 2016 Abeona Therapeutics, Inc. , a biopharmaceutical company focused on...
02/29/16 06:03 AMAbeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Systemic AAV Phase 1/2 Clinical Study With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA) - [Marketwired] - Phase 1/2 dose escalation study of ABO-102 in 6-9 patients Natural history study in 25 patients establishes baseline for efficacy endpoints FDA previously granted both Orphan Drug Designation and Rare ...
02/24/16 08:36 AMAbeona Therapeutics, Inc. to Present on CRISPR/CAS9 Technology Platform Progress at CRISPR Precision Gene Editing Congress - [Marketwired] - Abeona Therapeutics, Inc. , a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced being ...
About Abeona Therapeutics

Abeona Therapeutics logoAbeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for rare diseases. The Company's programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, the Company is also developing rare plasma protein therapies including SDF Alpha (alpha-1 protease inhibitor) for inherited COPD using its SDF (Salt Diafiltration) ethanol-free process.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ABEO
  • CUSIP:
Key Metrics:
  • Previous Close: $2.71
  • 50 Day Moving Average: $2.77
  • 200 Day Moving Average: $2.81
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $83.30M
  • Current Quarter EPS Consensus Estimate: $-0.59 EPS
Additional Links:
Abeona Therapeutics (NASDAQ:ABEO) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha